This article review aims to evaluate the traditional usage, phytoconstituent, and pharmacological activities of Peronema canescens (PC) published between 1994 to 2021 and suggest directions for further in-depth research of PC as a medicinal resource. A literature review used relevant keywords to collect primary and secondary scientific papers from popular media databases such as Google Scholar, Scopus, PubMed, and Science Direct. The search keywords for papers included Peronema canescens, traditional usage, phytoconstituent, pharmacological activity, in vitro, in vivo, combined, or separated. Traditional usage of PC as medicine has been identified to treat various diseases such as toothache, malaria, fever, skin disorders, itching, bruising, and hypertension, as refreshing drinks, increasing stamina, and as food ingredients. Chemical constituents of PC were seven clerodane diterpenoid compounds, namely A2, A3, B1, B2, B3, C1, and D1 peronemin. Five of them are furanyl groups. Secondary metabolites contained in PC extract were phenols, triterpenoids, flavonoids, tannins, alkaloids, steroids, and saponins. In vitro, pharmacological activities of PC showed anti-plasmodium, anti-inflammatory, antioxidant, antidiabetic, cytotoxic, and antibacterial activities, had non-toxic effects, and did not cause teratogenic effects. In vivo studies of PC showed that PC could use as an immune booster, antiparasitic, anti-hyperuricemic, anti-plasmodium, antidiabetic, and antipyretic. Many phytoconstituent and pharmacological reports indicated that PC was an essential medicinal herb resource, and some of its traditional uses, including the treatment of fever, antiparasitic, anti-hypertension, malaria, and tonic drink, have been partially confirmed through modern pharmacological studies. Diterpenoids were the main active constituents. However, these crude extracts and isolated chemicals of PC required additional research to identify the effects, optimal dosage, mechanisms of action, long-term safety, and potential side effects. In addition, clinical research was necessary to support the therapeutic potential of PC.
Objective: This study aims to predict a bioactive compound from Peronema canescens (PC) with mechanisms inhibitor interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-α) potential as an immunomodulatory using in silico approach. Methods: Autodock 4 was used to accomplish computer-assisted drug design with molecular docking simulation to discover binding energy, inhibition constant, and interactions with an amino acid in bioactive compounds from PC against IL-6 and TNF-α receptors. Lipinski predicts the drug-likeness of a bioactive compound for the oral route of administration. ADMET profiling of bioactive compounds to predict pharmacokinetic properties with pkCSM ADMET. Results: The results showed that the best binding energy, inhibition constant, and interactions with an amino acid of peronemin C1 against IL-6 and TNF-α receptors were (-7.19 kcal/mol; 5.39 nM; Arg 179, Arg 182, Gln 175), and (-8.86 kcal/mol; 320.42 nM; Tyr 119, Tyr 59, and Gly 121), respectively. All bioactive compounds from PC met Lipinski's rule of five requirements for oral administration. ADMET prediction results all bioactive compounds from PC are non-mutagenic, except peronemin D1 is mutagenic. Conclusion: The peronemin C1 bioactive compounds from PC have good immunomodulatory potential, effectively inhibiting human IL-6 and TNF-α receptors using in silico approach.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.